Augmenix, a medical technology company that develops, manufactures, and sells proprietary absorbable hydrogels that separate and protect organs at risk during radiotherapy and interventional procedures, announced that the first patients have been treated with SpaceOAR hydrogel at the Chaim Sheba Medical Center in Tel Hashomer, Israel. SpaceOAR hydrogel is an absorbable prostate-rectum spacer that reduces rectal injury during prostate radiotherapy.
Avinger has announced positive two-year clinical data from the pivotal VISION study of the company’s Lumivascular technology. Twenty-four-month follow-up results from 89 patients were presented by Patrick Muck, chief of Vascular Surgery at Good Samaritan Hospital in Cincinnati, USA, at New Cardiovascular Horizons (NCVH) in New Orleans, USA. This includes an additional 34 patients beyond the interim data set presented on January 25, 2017.
Bard’s Lutonix 035 drug-coated balloon PTA catheter (DCB) has been granted premarket approval (PMA) by the US Food and Drug Administration (FDA) for a new indication and is now available for sale in the USA.
Biotronik has announced that 12-month data from the BIOFLEX-I study have demonstrated the safety and efficacy of the company’s Pulsar-18 self-expanding stent for blocked superficial femoral artery treatment.
BTG and the Society of Interventional Oncology (SIO) have expanded their commitment to the Immuno-oncology /interventional oncology research grant programme, by announcing a second round of funding available to investigators.
“As interventional radiology is established as a free standing specialty, an international outreach effort to establish guidelines for different interventional treatments is certainly needed,” Constantinos T Sofocleous, Memorial Sloan Kettering Cancer Center, New York, USA, and professor of Radiology, Weill Medical College of Cornell University, New York, tells Interventional News. Sofocleous is chair of the Scientific Programme Committee of World Conference on Interventional Oncology (WCIO) 2016.
A randomised, double-blind, placebo-controlled trial evaluating the efficacy of prophylactic dexamethasone in preventing the most frequent adverse events of transcatheter arterial chemoembolization (TACE) in patients with hepatocellular carcinoma found it to be more effective than a placebo regimen.
While further refining where radioembolization should optimally lie in current treatment paradigms for the most common liver-confined or liver-dominant cancers is important, a honing of current administration protocols is also possible, writes Suvranu Ganguli, Boston, USA.
A retrospective review of single-institution experience, published in July in the Journal of Vascular and Interventional Radiology (JVIR), suggests that percutaneous image-guided ablation is feasible, well tolerated and achieves “acceptable” local tumour control rates.
The US FDA has approved the investigational device exemption (IDE) study to evaluate the safety and efficacy of IN.PACT AV access drug-coated balloon as a treatment for failing arteriovenous fistulas in end-stage renal disease patients.
Gore has announced the first patient implant of conformable thoracic stent graft with Active Control System after receiving CE mark last month. The first implant was performed by Giovanni Torsello and Martin Austermann at St. Franziskus Hospital, Munster, Germany. The new device will be formally launched in European regions later this year.
The Gore Viatorr TIPS endoprosthesis with Controlled Expansion, a new device configuration developed by Gore, may reduce portal hypertension treatment complications, even when compared to the Gore Viatorr TIPS endoprosthesis, Gore’s legacy TIPS device. The latter has a strong history of patency and proven performance at fixed diameters. These findings were obtained from the abstract presented at The International Liver Congress 2017 in Amsterdam.
The Montpellier University Hospital (Montpellier, France) has inaugurated an avant-garde interventional radiology intervention room in the Department of Interventional Radiology at the St-Eloi Hospital.
Medtronic has announced recent reimbursement approvals in both France and Belgium.
Johnson and Johnson Medical Devices Companies introduced Cerenovus, its new neurovascular business, at the Society of NeuroInterventional Surgery 14th Annual Meeting (SNIS; 24–28 July, Colorado Springs, USA).
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos